There are currently 17 active clinical trials seeking participants for Hepatic Impairment research studies. The states with the highest number of trials for Hepatic Impairment participants are Florida, Texas, California and Tennessee.
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
NCT06997276
Recruiting
The purposes of this study are to determine: * The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/21/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Healthy, Hepatic Impairment
Register for Updates
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
NCT06952634
Recruiting
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/29/2025
Locations: Orange County Research Center, Lake Forest, California +3 locations
Conditions: Hepatic Impairment
Register for Updates
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
NCT06740799
Recruiting
This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/13/2024
Locations: Clinical Pharmacology of Miami, LLC, Miami, Florida +2 locations
Conditions: Hepatic Impairment
Register for Updates
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
NCT06535399
Recruiting
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/01/2024
Locations: Arizona Liver Health, Chandler, Arizona +5 locations
Conditions: Hepatic Impairment, Healthy Volunteers
Register for Updates
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528
Recruiting
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/10/2024
Locations: Local Institution - 0006, Miami Lakes, Florida +5 locations
Conditions: Hepatic Impairment, Healthy Volunteers
Register for Updates